Integrative NGS testing reveals clonal dynamics of adverse genomic defects contributing to a natural progression in treatment-naïve CLL patients.

Autor: Navrkalova V; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.; Center of Molecular Medicine, CEITEC-Central European Institute of Technology, Masaryk University, Brno, Czech Republic.; Department of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic., Plevova K; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.; Center of Molecular Medicine, CEITEC-Central European Institute of Technology, Masaryk University, Brno, Czech Republic.; Department of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic., Radova L; Center of Molecular Medicine, CEITEC-Central European Institute of Technology, Masaryk University, Brno, Czech Republic., Porc J; Center of Molecular Medicine, CEITEC-Central European Institute of Technology, Masaryk University, Brno, Czech Republic.; Department of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic., Pal K; Center of Molecular Medicine, CEITEC-Central European Institute of Technology, Masaryk University, Brno, Czech Republic., Malcikova J; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.; Center of Molecular Medicine, CEITEC-Central European Institute of Technology, Masaryk University, Brno, Czech Republic., Pavlova S; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.; Center of Molecular Medicine, CEITEC-Central European Institute of Technology, Masaryk University, Brno, Czech Republic., Doubek M; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.; Center of Molecular Medicine, CEITEC-Central European Institute of Technology, Masaryk University, Brno, Czech Republic.; Department of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic., Panovska A; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic., Kotaskova J; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.; Center of Molecular Medicine, CEITEC-Central European Institute of Technology, Masaryk University, Brno, Czech Republic.; Department of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic., Pospisilova S; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.; Center of Molecular Medicine, CEITEC-Central European Institute of Technology, Masaryk University, Brno, Czech Republic.; Department of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic.

Publikováno v: British journal of haematology [Br J Haematol] 2024 Jan; Vol. 204 (1), pp. 240-249. Date of Electronic Publication: 2023 Dec 07.

EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia

Autor: Young, E, Noerenberg, D, Mansouri, L, Ljungström, V, Frick, M, Sutton, L-A, Blakemore, SJ, Galan-Sousa, J, Plevova, K, Baliakas, P, Rossi, D, Clifford, R, Roos-Weil, D, Navrkalova, V, Dörken, B, Schmitt, CA, Smedby, KE, Juliusson, G, Giacopelli, B, Blachly, JS, Belessi, C, Panagiotidis, P, Chiorazzi, N, Davi, F, Langerak, AW, Oscier, D, Schuh, A, Gaidano, G, Ghia, P, Xu, W, Fan, L, Bernard, OA, Nguyen-Khac, F, Rassenti, L, Li, J, Kipps, TJ, Stamatopoulos, K, Pospisilova, S, Zenz, T, Oakes, CC, Strefford, JC, Rosenquist, R, Damm, F

Publikováno v: Sygma
Institutional Repository for Molecular Medicine (MDC)
Leukemia, 31(7), 1547-1554. Nature Publishing Group
Leukemia, vol 31, iss 7

Recurrent mutations within EGR2 were recently reported in advanced-stage chronic lymphocytic leukemia (CLL) patients and associated with a worse outcome. To study their prognostic impact, 2403 CLL patients were examined for mutations in the EGR2 hots

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::68e8440f22f726f4a7ad0c11d529803d

Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes.

Autor: Olbertova H; Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic.; Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic., Plevova K; Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic.; Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.; Department of Medical Genetics and Genomics Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic., Pavlova S; Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic.; Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic., Malcikova J; Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic.; Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic., Kotaskova J; Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic.; Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic., Stranska K; Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic.; Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic., Spunarova M; Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic., Trbusek M; Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic., Navrkalova V; Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic.; Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic., Dvorackova B; Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic., Tom N; Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic., Pal K; Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic., Jarosova M; Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.; Department of Medical Genetics and Genomics Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic., Brychtova Y; Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic., Panovska A; Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic., Doubek M; Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic.; Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.; Department of Medical Genetics and Genomics Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic., Pospisilova S; Central European Institute of Technology, Masaryk University, 625 00, Brno, Czech Republic. sarka.pospisilova@ceitec.muni.cz.; Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. sarka.pospisilova@ceitec.muni.cz.; Department of Medical Genetics and Genomics Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic. sarka.pospisilova@ceitec.muni.cz.

Publikováno v: BMC cancer [BMC Cancer] 2022 Feb 03; Vol. 22 (1), pp. 137. Date of Electronic Publication: 2022 Feb 03.

LYmphoid NeXt-Generation Sequencing (LYNX) Panel: A Comprehensive Capture-Based Sequencing Tool for the Analysis of Prognostic and Predictive Markers in Lymphoid Malignancies.

Autor: Navrkalova V; Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic., Plevova K; Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic., Hynst J; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic., Pal K; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine II - Hematology and Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany., Mareckova A; Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic., Reigl T; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic., Jelinkova H; Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic., Vrzalova Z; Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic., Stranska K; Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic., Pavlova S; Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic., Panovska A; Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic., Janikova A; Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic., Doubek M; Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic., Kotaskova J; Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic., Pospisilova S; Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic. Electronic address: sarka.pospisilova@ceitec.muni.cz.

Publikováno v: The Journal of molecular diagnostics : JMD [J Mol Diagn] 2021 Aug; Vol. 23 (8), pp. 959-974. Date of Electronic Publication: 2021 Jun 01.

Genomic landscape of B-other acute lymphoblastic leukemia in an adult retrospective cohort with a focus on BCR-ABL1 -like subtype.

Autor: Hrabovsky S; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czechia.; Faculty of Medicine, Masaryk University, Brno, Czechia.; Czech Leukemia Study Group - for Life (CELL), Brno, Czechia., Vrzalova Z; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czechia.; Central European Institute of Technology (CEITEC), Brno, Czechia., Stika J; Central European Institute of Technology (CEITEC), Brno, Czechia., Jelinkova H; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czechia., Jarosova M; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czechia.; Faculty of Medicine, Masaryk University, Brno, Czechia.; Central European Institute of Technology (CEITEC), Brno, Czechia., Navrkalova V; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czechia.; Central European Institute of Technology (CEITEC), Brno, Czechia., Martenek J; Faculty of Medicine, Masaryk University, Brno, Czechia., Folber F; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czechia.; Faculty of Medicine, Masaryk University, Brno, Czechia.; Czech Leukemia Study Group - for Life (CELL), Brno, Czechia., Salek C; Czech Leukemia Study Group - for Life (CELL), Brno, Czechia.; Institute of Hematology and Blood Transfusion, Prague, Czechia.; Institute of Clinical and Experimental Hematology, First Faculty of Medicine, Charles University, Prague, Czechia., Horacek JM; Czech Leukemia Study Group - for Life (CELL), Brno, Czechia.; Fourth Department of Internal Medicine - Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czechia.; Department of Military Internal Medicine and Hygiene, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czechia., Pospisilova S; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czechia.; Faculty of Medicine, Masaryk University, Brno, Czechia.; Czech Leukemia Study Group - for Life (CELL), Brno, Czechia.; Central European Institute of Technology (CEITEC), Brno, Czechia., Mayer J; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czechia.; Faculty of Medicine, Masaryk University, Brno, Czechia.; Czech Leukemia Study Group - for Life (CELL), Brno, Czechia.; Central European Institute of Technology (CEITEC), Brno, Czechia., Doubek M; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czechia.; Faculty of Medicine, Masaryk University, Brno, Czechia.; Czech Leukemia Study Group - for Life (CELL), Brno, Czechia.; Central European Institute of Technology (CEITEC), Brno, Czechia.

Publikováno v: Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2021 Jun; Vol. 60 (6), pp. 760-770. Date of Electronic Publication: 2021 Mar 22.